Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)
Published: 12 July 2022| Version 1 | DOI: 10.17632/ms9xg8cb9g.1
Contributors:
Andrew Blauvelt, Richard Langley, Jean-Philippe Lacour, Andreas Wollenberg, Darryl Toth, Vivian Laquer, Stefan Beissert, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard Warren, Eric Simpson, Kristian ReichDescription
Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
Files
Institutions
LEO Pharma A/S
Categories
Dermatology, Clinical Trial, Atopic Dermatitis